RNXT8:30 AMRenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16threnovorx.com
RNXT8:30 AMRenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic CancerTrial Results • Phase 3renovorx.com
RNXT8:30 AMRenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatmentrenovorx.com
RNXT4:05 PMRenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue GrowthEnrollment • Phase 3Enrollment milestone Wed, Aug 12, 2026, 4:05 PM EDTGrenovorx.com
RNXT8:30 AMRenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic CancerEnrollment • Phase 3Enrollment completion Fri, Aug 7, 2026, 8:30 AM EDTGrenovorx.com
RNXT8:30 AMRenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumorsrenovorx.com
RNXT8:30 AMRenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13threnovorx.com
RNXT8:30 AMRenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ETrenovorx.com